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Background and purpose: Overviews of randomized patch trials by the Cochrane Collaboration suggest that a policy of
routine patching is preferable to routine primary closure. However, there is no systematic evidence that patch type,
whether prosthetic or vein, influences outcome after carotid endarterectomy (CEA).
Methods: Two hundred seventy-three patients were randomized to vein or thin-walled Dacron patch (Hemashield Finesse)
closure of the arteriotomy after 276 CEA procedures. Patients were reviewed clinically and with duplex ultrasound
scanning at 1, 6, 12, 24, and 36 months or until death. No patients were lost to follow-up. Cumulative statistical analyses
are presented for the 264 patients (269 CEAs) who actually received a randomized treatment allocation.
Results: Cumulative freedom from death or ipsilateral stroke at 3 years (including operative events) was 93.0% in the
Dacron patch group and 95.5% in the vein group P .42). Cumulative freedom from death or any stroke was 91.5% after
Dacron patch closure and 93.9% after vein closure (P  .46). Cumulative freedom from recurrent stenosis greater than
70% or occlusion at 3 years was 92.9% for patients randomized to the Dacron patch group and 98.4% for patients
randomized to the vein group (P  .03). At 3 years the incidence of stroke in the carotid territory not operated on was
1.0% in 93 patients with no contralateral internal carotid artery disease at randomization, and increased to 1.3% in 78
patients with 1% to 69% stenosis, and 2.0% in 51 patients with contralateral 70% to 99% stenosis. No late strokes occurred
distal to 42 occluded contralateral internal carotid arteries.
Conclusions: Patch type has no influence on early operative risk, no association with enhanced patterns of thrombogenicity
in the early postoperative period, and no influence on risk for ipsilateral or any stroke at 3 years. Dacron patches were,
however, associated with a significantly higher incidence of recurrent stenosis at 3 years, with most occurring within 6 to
12 months of surgery. However, the higher incidence of recurrent stenosis was not associated with a parallel increase in
late stroke, and in this study a program of serial ultrasound surveillance could not have prevented one ipsilateral stroke.
(J Vasc Surg 2004;39:985-93.)The role of patch closure after carotid endarterectomy
(CEA) remains one of the most enduring single issue
subjects in vascular surgery. A systematic review of the six
randomized trials published to date suggests that a policy of
routine patching is preferable to routine primary closure.1
Existing evidence from randomized controlled trials also
suggests that patch type, whether prosthetic or vein, has no
influence on short-term results.1 Advantages of vein in-
clude optimal handling and resistance to infection, and the
principal disadvantages include early rupture, groin wound
complications, and loss of a valuable conduit for future
reconstructive procedures. Advantages of prosthetic mate-
rial include instant availability, avoidance of vein harvest
From the Departments of Vascular Surgerya and Neurology,b The Leicester
Royal Infirmary.
Supported by research grants from the UK Stroke Association. Funds for the
salary of the theater technician who monitored all patients with transcra-
nial Doppler ultrasound in the perioperative period were provided by
Boston Scientific, Natick, Mass.
Competition of interest: none.
Additional material for this article may be found online at www.mosby.
com/jvs.
Reprint requests: A. R. Naylor, MD, FRCS, Department of Surgery, Clinical
Sciences Building, Leicester Royal Infirmary, Leicester, UK (e-mail:
arnaylor@hotmail.com).
0741-5214/$30.00
Copyright © 2004 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2004.01.037complications, and preservation of groin saphenous vein for
future use; its main disadvantage is infection.2
The goals of the current study were twofold: to test the
hypothesis that prosthetic and vein patches are of equal
thrombogenicity in the early postoperative period, and to
determine whether there are any long-term differences in
rates of stroke and recurrent stenosis relative to patch type.
In a previous publication3 we reported no differences in
operative risk (death, any stroke within 30 days) relative to
patch type. Specifically, the incidence of high-grade post-
operative embolization, predictive of progression to early
postoperative carotid thrombosis,4-8 was identical for vein
and prosthetic patches.3 The current study presents long-
term (3 years) follow-up data for the cohort surviving 30
days after surgery.
MATERIAL AND METHODS
Study design. The trial method was described in an
earlier publication detailing 30-day outcomes.3 In sum-
mary, the study was approved by the Leicestershire Area
Ethics Committee, and patients were entered with in-
formed consent. Two hundred ninety-three patients under-
went CEA at the Leicester Royal Infirmary between De-
cember 1, 1997, and December 31, 1999, and were
considered for inclusion. Twenty patients were excluded
because of refusal to give informed consent (n  10),
previous bilateral varicose vein surgery (n  6), osteomy-985
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1), and combined common carotid angioplasty and CEA
(n  1). Two hundred seventy-three patients were there-
fore randomized within the trial. Before trial commence-
ment, 300 computer-generated, random treatment meth-
ods (vein or Dacron patch) were consecutively numbered
and sealed in opaque envelopes, and were allocated consec-
utively, immediately after induction of anesthesia, starting
with envelope 1. Three patients underwent bilateral CEA
during the course of the study. In accordance with accepted
trial practice, these patients received the same type of patch
as was randomly allocated at the first operation. Nine
patients did not receive the allocated patch (Table I). Five
required vein bypass, because of excessive endarterectomy
zone thinning (n  2) or marked distal internal carotid
artery (ICA) coiling (n 3). One patient had a hypoplastic
ICA, which was ligated after on-table angiography. Post-
operatively the patient received anticoagulation therapy.
The remaining three patients had poor quality groin saphe-
nous vein at exploration, and a Dacron patch was inserted.
Baseline demographic data are summarized in Table II.
Both groups were equally matched for comorbidity, pre-
sentation, degree of stenosis, and antiplatelet therapy.
Carotid endarterectomy. Antiplatelet therapy was
not stopped before surgery. CEA was performed by a
consultant vascular surgeon (n 154) or supervised trainee
(n 122), with use of normotensive, normocarbic general
anesthesia, loupe magnification, systemic heparinization
(5000 U), routine shunting (Pruitt-Inahara, Ideas for
Medicine), and routine tacking sutures to the distal intimal
step. In patients randomized to the vein group a segment of
long saphenous vein was harvested from the groin and
anastomosed with 6:0 polypropylene suture (Prolene;
(Ethicon). In patients randomized to the Dacron patch
group a Hemashield Finesse patch (Boston Scientific,
Natick, Mass) was inserted, with 6:0 polypropylene suture.
Blood flow velocity in the middle cerebral artery was mon-
itored throughout, with 2-MHz pulsed-wave transcranial
Doppler ultrasound with a fixed-head probe system
(Scimed UK, Bristol, England) protected by a semicircular
metal head guard with recording onto digital audiotape for
offline analysis of emboli.9,10 A 5-mm segment of the
anastomosis, adjacent to the orifice of the external carotid
artery, was left open. The shunt was removed, and the
lumen was vented and irrigated with heparinized saline
Table I. Treatment changes after randomization
Dacron Vein
Number of patients randomized 136 137
Bilateral patients receiving same patch 1 2
Total procedures 137 139
Carotid bypass procedures performed 3 2
Internal carotid artery ligation 1 0
Unsuitable vein (Dacron patch
inserted)
0 3
Actual allocation of patch 133 134solution. Before final closure and restoration of flow, the
lumen was inspected with a flexible hysteroscope (Olympus
1070-48), to exclude technical error.10 In this series three
patients (2.2%) randomized to the Dacron patch group
underwent repair of an intimal flap after angioscopy, and in
six patients (4%) luminal thrombus was aspirated. Two
patients (1.5%) randomized to the vein group required
intimal flap repair, and in eight (6%) luminal thrombus was
aspirated.
After the procedure patients were transferred to the
high-dependency unit for TCD monitoring. All emboli
detected in the first 3 postoperative hours were recorded
onto digital audiotape and quantified offline. Previous
work from this unit has shown that postoperative emboli
are exclusively particulate.9 Sustained postoperative embo-
lization is highly predictive of progression to thrombosis
and stroke,4-8 and this phase can be abolished with incre-
mental infusion of Dextran.10,11 Accordingly, in any pa-
tient who had more than 25 emboli in any 10-minute
period incremental infusion of Dextran 40 was begun.10
The number of emboli and rate of embolization were
quantified for each patient, as was the requirement for
Dextran therapy.
Postoperative assessment. All patients were assessed
within 24 hours of surgery by the trial neurologist (H.A.),
who documented any new neurologic deficit or cranial
nerve injury. Any new neurologic deficit lasting longer than
24 hours was classified as a stroke, and the patients were
assessed with computed tomography or at autopsy, duplex
scanning of the extracranial ICA, and TCD assessment of
the intracranial vessels. The neurologist reassessed all sur-
vivors at 30 days, and those with perioperative stroke
underwent assessment of severity with the Oxfordshire
Handicap Score (OHS).12 A minor, nondisabling stroke
was scored as 0 to 2 on the OHS scale, and a disabling
stroke was scored as 3 to 6 on the OHS scale. All survivors
underwent color duplex scanning (ATL Ultramark; Bothel,
Wash) of the artery operated on at 30 days by the same
vascular technologist (S.S.). Attention was directed toward
measuring the maximum diameter of the carotid bulb,
excluding carotid occlusion and diagnosing stenosis greater
than 70%. In this unit, duplex ultrasound scanning criteria
for diagnosis of severe recurrent stenosis (70%) are peak
systolic velocity greater than 250 cm/s in conjunction with
end-diastolic velocity greater than 120 cm/s. If there was
any persisting doubt, peak systolic velocity ratio (internal
carotid artery/common carotid artery) of greater than 4.0
was used.
All survivors were reviewed clinically and with duplex
ultrasound surveillance of the ICA operated on, at 6 and 12
months and annually thereafter up to 3 years, when they
were discharged from review. Two patients refused to
attend follow-up clinics after 12 months had elapsed. Their
clinical status, but not duplex scanning, was monitored out
to 3 years by telephone review with the family doctor.
Three patients moved to distant health regions, where
vascular colleagues maintained clinical and ultrasound sur-
veillance. Accordingly, 267 of 269 survivors of the opera-
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for 3 years or until death. In those situations where the
patient failed to attend for review, died, or had a stroke
between review appointments, the required end point data
were obtained by means of scrutiny of death certificates,
telephone calls to the family physician or hospital clinician,
or hospital case note review. Accordingly, no patient was
lost to follow-up in this study. However, one patient had a
fatal late stroke, with laterality and cause not clarified after
review of the family physician records. For the purposes of
statistical analysis, this was assumed to be ipsilateral and
ischemic.
Statistical analysis. The study data were analyzed on a
per-protocol principal. Thus data for the nine patients who
were randomized but did not receive the allocated treat-
ment were excluded from the principal analyses. However,
the outcomes in these patients are presented separately.
Kaplan-Meier curves were used to plot cumulative 3-year
survival, freedom from ipsilateral stroke (including opera-
tive risk), any stroke (including operative risk), and recur-
rent stenosis. The log-rank test was used to determine
statistical significance from the Kaplan-Meier curves. P 
.05 was considered statistically significant.
RESULTS
Summary of 30-day outcomes
The 30-day risk for death or any stroke was 2.2% in the
Dacron patch group and 3.7% in the vein group and who
received the treatment allocation (Table III). There were
Table II. Preoperative patient demographic data
Da
n
Gender
Male 94
Female 43
Age (y)
Median 71
95% CI 67–73
Treated hypertension 90
Previous MI 26
Treated angina 39
Diabetes 22
Current smoker 37
Asymptomatic disease 15
TIA or amaurosis 82
Stroke 40
Unilateral 70% stenosis 85
Bilateral 70% stenosis 31
Stenosis  contralateral occlusion 21
Aspirin dose (mg)
Median 75
95% CI 90–113
Aspirin therapy alone 108
Aspirin  dipyridamole 16
Dipyridamole therapy alone 4
Warfarin therapy alone 8
No antiplatelet or anticoagulant therapy 1
MI, Myocardial infarction; TIA, transient ischemic attack; CI, confidence inno patch infections or early vein patch ruptures. High-rate
postoperative embolization requiring adjuvant Dextran
therapy to prevent progression to thrombosis was necessary
in nine patients (6.8%) randomized to the Dacron patch
group and seven patients (5.2%) allocated to the vein group
(P .62). No survivor had any evidence of residual stenosis
greater than 70% or occlusion at 30 days. The median
carotid bulb diameter at 30 days was 10.8 mm (95% confi-
dence interval, 10.3-10.8) in the Dacron patch group and
12.0 mm (95% confidence interval, 11.9-12.6) in the vein
patch group (P  .001). A fuller account of all of the early
outcomes is published elsewhere.3
Late outcomes
Survival. Thirty-one patients (11.2%) died during fol-
low-up. Cumulative survival at 3 years was 85.8% in the vein
patch group and 87.2% in the Dacron patch group (P 
.741). Thirteen patients (42%) died of cardiac causes, seven
(23%) of cancer, and five (16%) after stroke. Six (19%) died
of other causes (pneumonia (n  4), complications of
gastric surgery (n  1), or ruptured aortic aneurysm (n 
1). Of the five patients with a fatal stroke, the laterality was
unknown in one patient, and for statistical purposes was
assumed to be ischemic and ipsilateral (Table IV). Two of
the remaining four strokes were documented as ipsilateral
ischemic, and two were contralateral ischemic.
Late stroke. Twelve patients (4.5%) had late stroke,
including the fatal events described above (Table IV). To
our knowledge, no late intracranial hemorrhage occurred
Vein
P% n %
.48
89
50
.30
70
69–72
66 91 65 1.00
19 33 24 .45
28 42 30 1.00
16 21 15 1.00
27 31 22 .40
11 16 12 .90
60 70 50 .12
29 53 38 .13
62 91 65 .53
23 24 17 .37
15 24 17 .75
.91
75
90–110
79 101 73 .27
12 25 18 .18
3 5 4 1.00
6 8 6 1.00
0.7 0 0 .97
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are shown in Fig 1, and cumulative freedom from any
stroke, including operative risk, in Fig 2. Three-year cumu-
lative freedom from ipsilateral stroke, including operative
events, was 95.5% in the vein patch group and 93.0% in the
Dacron patch group (P  .42). Three-year cumulative
freedom from any stroke, including operative events, was
93.9% in the vein patch group and 91.5% in the Dacron
patch group (P  .462).
Seven patients randomized to receive Dacron patch
closure had a late ipsilateral stroke (Table IV). Three
strokes were fatal, and two were nondisabling. None of
these five patients had any evidence of recurrent ipsilateral
stenosis. The two remaining patients had disabling ipsilat-
eral strokes. Duplex scanning revealed carotid occlusion in
one patient, who had 20% recurrent stenosis at the preced-
ing surveillance scanning 4 months earlier. The second
patient had greater than 70% recurrent stenosis. Paradoxi-
cally, the stroke in this patient followed attempted angio-
plasty of the recurrent lesion. This patient had poor collat-
eralization at TCD (clamp middle cerebral artery velocity
10 cm/s), and when the severe recurrent stenosis was
detected at 12 months it was thought appropriate to inter-
vene. Angioplasty of the lesion was successful, but it re-
curred within 5 months. The patient had a disabling stroke
after repeat angioplasty, despite use of a distal protection
device. Only one patient randomized to the Dacron patch
group had a contralateral carotid territory stroke during
follow-up, with no significant ICA stenosis at randomiza-
tion or after stroke onset.
In the vein patch group, only one patient had an
ipsilateral ischemic stroke (disabling) during follow-up.
Duplex scanning revealed no evidence of any significant
recurrent stenosis. Contralateral carotid territory strokes
occurred in two patients. One was known preoperatively to
have 80% to 90% contralateral ICA stenosis, whereas the
other had no significant disease.
Patch rupture and infection. No patients in this se-
ries had vein patch rupture or prosthetic infection during
follow-up.
Table III. Thirty-day morbidity and mortality
Dacron Vein
Operative deaths
Acute cardiac failure 1 1
Brainstem stroke 0 1
Intracranial hemorrhage 0 1
Disabling stroke
MCA embolism 0 1
cardioembolic 1 0
Nondisabling stroke
Intracranial hemorrhage 0 1
MCA embolism 1 0
Cranial nerve injury
Mandibular branch of facial nerve 1 2
Hypoglossal nerve 3 2
Recurrent laryngeal nerve 2 2
MCA, Middle cerebral artery.Late ipsilateral recurrent stenosis or occlusion.
Eleven patients (4.1%) had recurrent stenosis greater than
70% (n  10) or occlusion (n  1) during follow-up.
Cumulative freedom from recurrent stenosis greater than
70% or occlusion at 3 years (Fig 3) was 98.4% in the vein
patch group and 92.9% in the Dacron patch group (P 
.031). Our policy (with the one exception described above)
was to not intervene in patients with severe ipsilateral
recurrent stenosis; the remainder were managed conserva-
tively. Excluding the patient with stroke after angioplasty,
only one of 10 patients with significant recurrent disease
had a late ipsilateral stroke. After stroke onset, the pa-
tient was found to have an occluded carotid artery. At
review of the preceding surveillance scan from 4 months
previously, however, only 20% recurrent stenosis was
noted.
Cumulative freedom from development of recurrent
stenosis greater than 50% or occlusion is detailed in Fig 4.
Patients in the vein patch group had a significantly lower
rate of moderate or severe recurrent stenosis at 3 years
(97.7% vs 87.6%; P  .002). Of interest, most stenoses in
the Dacron patch group developed within the first 6 to 12
months after operation, but few progressed from 50% to
69% stenoses to 70% to 99% stenoses (note the stable
plateau in Fig 3).
Contralateral stroke. During the trial it was the pol-
icy of the unit not to offer CEA to patients with asymptom-
atic contralateral severe stenosis. Accordingly, only three
patients (1.1%) underwent staged, bilateral CEA in this
series. During follow-up, two male patients reported tran-
sient ischemic attacks (TIAs) in the territory of the ICA not
operated on. One had longstanding contralateral 75% ste-
nosis before the first operation; the other had 55% stenosis
at the time of contralateral CEA, which progressed to 80%
at examination after onset of TIAs. One female patient
without symptoms, with longstanding contralateral 80%
stenosis, underwent prophylactic contralateral CEA, be-
cause recurrent 90% stenosis developed within 6 months in
the ICA operated on.
Table IV. Causes and disability of late stroke
Dacron Vein
Fatal
Ipsilateral 3* 0
Contralateral 0 2
Vertebrobasilar 0 0
Disabling
Ipsilateral 2 1
Contralateral 0 0
Vertebrobasilar 0 0
Nondisabling
Ipsilateral 2 0
Contralateral 1 0
Vertebrobasilar 1 0
*One of these three patients was listed on the death certificate as having died
of “stroke.” We were unable to determine the laterality and cause of this. In
line with conventional statistical practice, this event has been included as
ipsilateral and ischemic.
perio
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had late stroke in the territory of the (contralateral) ICA
not operated on. Two were fatal, one was nondisabling.
One patient was known to have 80% to 90% ICA stenosis;
the other had 45% stenosis when admitted with stroke. The
remaining patient with stroke had no evidence of contralat-
eral carotid disease when examined.
Postoperative duplex ultrasound scanning of the ICA not
operated on was not routinely performed during follow-up,
Fig 1. Cumulative freedom from ipsilateral stroke, incl
dence intervals. Number of patients at risk in each time
Fig 2. Cumulative freedom from any stroke, including
intervals. Number of patients at risk in each time periodlargely because of logistical reasons. Accordingly, the risk for
late stroke in the contralateral ICA territory was correlated
with the preoperative status of the ICA not operated on
(Table V). One of 93 (1.0%) patients with no contralateral
carotid disease had a late stroke in the carotid territory not
operated on, during 3 years of follow-up, increasing to 1.3%
(1 of 78) in patients with 1% to 69% stenoses and 2.0% (1 of
51) in patients with contralateral 70% to 99% stenosis. No late
strokes occurred distal to 42 occluded carotid arteries.
operative events. Kaplan-Meier curve with 95% confi-
d listed.
ative events. Kaplan-Meier curve with 95% confidence
.udingoper
listed
ach t
ach t
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cation. Nine patients did not receive the randomized
treatment allocation (see Methods), and were not included
in the cumulative data presented above. The principal
outcomes in these nine patients are summarized in Table VI
(online only). All survived during the 3 years of follow-up,
and remained neurologically asymptomatic. Five under-
went saphenous vein bypass. In two of these, severe recur-
rent stenoses developed, which were treated with angio-
plasty. One patient underwent ligation of a hypoplastic ICA,
Fig 4. Cumulative freedom from ipsilateral recurrent ste
95% confidence intervals. Number of patients at risk in e
Fig 3. Cumulative freedom from ipsilateral recurrent ste
95% confidence intervals. Number of patients at risk in eand received anticoagulation therapy postoperatively. The
three remaining patients were randomized to vein patching,
but actually received a Dacron patch, because the groin saphe-
nous vein was deemed unusable at exploration. None had
symptoms or recurrent stenoses during follow-up.
DISCUSSION
The question of whether a surgeon should patch the
arteriotomy after CEA has become one of the most endur-
ing single issue subjects relating to outcomes in carotid
greater than 50% or occlusion. Kaplan-Meier curves with
ime period listed.
greater than 70% or occlusion. Kaplan-Meier curves with
ime period listed.nosisnosis
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surgeon patched routinely, selectively, or never more likely
reflected training experience and personal dogma rather
than being based on evidence. However, a systematic re-
view of published randomized trials by the Cochrane Col-
laboration showed that a policy of routine patching was
preferred to routine primary closure, conferring a threefold
to fourfold excess reduction in perioperative stroke or
thrombosis and late stroke or recurrent stenosis.1 Accord-
ingly, surgeons are probably using a patch in more patients
than previously, but two outstanding questions remain.
The first is whether selective patching is preferable to
routine patching. Second, if we assume that either patching
strategy is preferable to routine primary closure, is there any
evidence that patch type, prosthetic or vein, influences
outcome? No randomized trials have compared selective
versus routine patching, and none are known to be in
progress. Accordingly, the answer to the first question is
likely to remain unanswered.
In 1997 the Cochrane Collaboration performed a
meta-analysis of the randomized trials of prosthetic ver-
sus vein patch closure.1 From the limited number of
randomized patients, the authors concluded that there
was no evidence to support preferential use of vein rather
than prosthetic patch material. Since 1997 the number
of published randomized trials comparing patch type of
closure has increased to seven.14-20 In a previous report
of 30-day outcomes from the current study, we found no
evidence that patch type influences operative risk.3 A
similar observation was made in four other randomized
trials.14,17-19 In particular, the Leicester trial showed no
evidence that prosthetic patches are more thrombogenic
than vein, as measured by the incidence of high-grade,
sustained embolization that has otherwise been shown to
be highly predictive of progression to carotid thrombo-
sis.4-8 No postoperative carotid thrombosis occurred in
the study cohort. However, this is at odds with the
conclusions of one other randomized trial, which com-
pared polytetrafluoroethylene (PTFE) with standard-
thickness Hemashield Dacron patches.20. This study ob-
served a 7% stroke rate with Dacron patches, versus 0%
with PTFE patches, due principally to a 5% early throm-
bosis rate with Dacron patches.20 This is a much higher
rate of thrombosis than is usually reported in the world
Table V. Three-year risk for late stroke in carotid
territory not operated on, relative to disease status before
surgery
Preoperative
stenosis (%) n %
Strokes at 3
years
n %
0 93 35 1 1.0
1–69 78 30 1 1.3
70–99 51 19 1 2.0
Occlusion 42 16 0 0.0literature,21 as was the 7% incidence of 50% to 99%
recurrent stenosis, in addition to occlusions, at 30 days in
patients who received Dacron patches.
Having established that there is still no systematic
evidence from the randomized trials that patch type
influences operative risk, what about the long-term re-
sults? These should be considered in two components:
stroke risk and recurrent stenosis. The current trial shows
no evidence that patch type influences the 3-year risk for
ipsilateral stroke or any stroke (Figs 1 and 2). A similar
observation was borne out in the other randomized
trials. Including operative events, 93% of patients in both
randomized arms of the trial were stroke-free at 3 years.
This is lower than comparable data from the European
Carotid Surgery Trial22 and the North American Symp-
tomatic Carotid Endarterectomy Trial,23 but compara-
ble with the 1-year risk from the recent randomized
patch trial from The Cleveland Clinic.19 In the absence
of any other explanation, we have attributed the im-
proved long-term outcomes, first, to our routine use of
intraoperative monitoring and completion angioscopy to
minimize the risks for undetected technical error predis-
posing to both early and late stroke. In this study no
patient recovered from anesthesia with a stroke, no pa-
tient had perioperative carotid thrombosis, and no sur-
viving patient had duplex ultrasound evidence of residual
or recurrent stenosis greater than 70% at 30 days. This
suggests that the goals of our quality control program
were achieved. The second contributory factor to im-
proved late outcomes may be the discipline of having to
regularly review patients for trial purposes, which en-
abled the surgeon or neurologist to reinforce the impor-
tance of antiplatelet therapy, blood pressure control, and
appropriate statin therapy with the patient.
The literature, however, contains conflicting evidence
regarding the risk for late recurrent stenosis in patients
randomized to receive vein or prosthetic patches. Abu-
Rahma et al15 observed a higher cumulative risk for recur-
rent stenosis greater than 50% at 48 months for vein patches
as opposed to PTFE patches (16% vs 4%), and O’Hara et
al19 observed a rate of about 5% for recurrent stenosis
greater than 60% with vein and Dacron patches. In the
current series 99% of patients surviving to 30 days were
serially followed up with ultrasound, to 3 years or death.
Patients randomized to vein patching had a significantly
lower incidence of significant (70%) recurrent stenosis or
occlusion, compared with patients with Dacron patches
(1.6% vs 7.1%; P .031). When the threshold was lowered
to include moderate (50%) stenosis, this difference be-
came more apparent (2.3% vs 12.4%; P .002). However,
it should again be noted that even though recurrent steno-
sis rates were higher in patients with the Dacron patch, this
did not translate into a higher risk for stroke. This is
presumably because most restenosis was secondary to inti-
mal hyperplasia, which carries a more benign prognosis
than do primary atherosclerotic lesions.
This study has also contributed to the enduring debate
regarding the role of serial ultrasound surveillance, princi-
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did not implement a policy of intervening in patients
with severe, recurrent restenosis or severe contralateral
(asymptomatic) disease. With the exception of one neu-
rologically asymptomatic patient who did undergo an-
gioplasty, all other patients (n  10) were managed
conservatively. Only one patient subsequently had an
ipsilateral stroke and severe recurrent disease. At exami-
nation, a carotid occlusion was found, but a review of the
preceding surveillance scan showed only 20% recurrent
stenosis. In short, a program of serial ultrasound surveil-
lance in 264 trial patients (1187 scans over 3 years) did
not prevent any ipsilateral stroke. Most important, seven
ipsilateral strokes occurred despite a full program of
surveillance, all with no evidence of any significant recur-
rent stenosis (50%) when investigated.
The other reason cited for continued ultrasound
surveillance is disease severity or progression in the con-
tralateral ICA. In this study we were unable, because of
logistical reasons, to serially scan the ICA not operated
on, and therefore cannot specifically comment on the
role of surveillance in this situation. However, two ob-
servations suggest that such a program would still not
have offered much clinical benefit. First, only three pa-
tients had a late stroke in the territory of the ICA not
operated on during 3 years of follow-up. Only one had
severe (70%-99%) stenosis at the time of stroke. Second,
the 3-year risk for stroke in the territory of the ICA not
operated on was virtually identical (range, 1.0%-2.0%),
irrespective of the degree of stenosis in the contralateral
ICA at the time of randomization. Most important, only
1 of 51 patients (2.0%) with known contralateral 70% to
99% stenosis at the time of randomization had an unher-
alded stroke during the 3-year follow-up.
In conclusion, this trial was different from most other
contemporary studies, because there was no policy for
intervening in patients with severe recurrent stenosis or
contralateral disease. This randomized study shows that
patch type has no influence on early operative risk, no
association with enhanced patterns of thrombogenicity
in the early postoperative period, and no influence on the
risk for ipsilateral stroke or any stroke at 3 years. Dacron
patches are, however, associated with a significantly
higher incidence of recurrent stenosis (50%-100% and
70%-100%) at 3 years, with most occurring within the
first 6 to 12 months after surgery. However, the higher
incidence of recurrent stenosis was not associated with a
parallel increase in late stroke risk, and in this study a
program of serial ultrasound surveillance did not prevent
one ipsilateral stroke.
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Joseph P. Archie, MD, Raleigh, NC
This prospective randomized trial supports the conclusions of
most other similar studies indicating that the perioperative and
midterm stroke and mortality rates for saphenous vein–patched
and synthetic-patched carotid endarterectomy (CEA) are similar
and low. It raises controversy concerning the management of
severe recurrent stenosis, the value of ultrasound surveillance after
CEA, and the importance of the statistically significantly higher
rate of moderate (50%) and severe (70%) recurrent stenosis
with Dacron-patched CEA compared with vein-patched CEA. The
authors’ indication for intervention in high-grade recurrent steno-
sis is development of ipsilateral symptoms. While their protocol
allows for a superb natural history study of CEA, for which they are
to be congratulated, it also negates the issue of the value of
follow-up duplex scanning. On the basis of the observation that
none of 11 patients in whom greater than 70% recurrent stenosis
developed had symptoms, they recommend not performing serial
ultrasound surveillance after CEA. Although it is well known that
the incidence of stroke due to early and midterm recurrent stenosis
is low, the risk of repeat intervention may be significantly lower.
Eleven patients with recurrent stenosis is too small a number to
hang one’s hat on, particularly given the 95% confidence interval of0% to 26% for observing no events in 11 samples (binomial
distribution). The 7.1% rate of greater than 70% recurrent
stenosis and the 12.4% rate of greater than 50% recurrent
stenosis at 3 years reported in this study for Dacron-patched
CEA are similar to what others have found. These 3-year rates
only partially reflect what may occur later, when the major
component of recurrent disease is atherosclerotic, not the ear-
lier and more benign hyperplasia. Even though only 12% of the
patients in this trial were operated on because of asymptomatic
stenosis, it would be difficult for me not to offer serial ultra-
sound surveillance to patients operated on to treat asymptom-
atic stenosis and who received the Dacron patch. Further, if I
had a high-grade carotid stenosis, I probably would not agree to
receive a Dacron patch if I knew the moderate to severe recur-
rence rate was 7% to 12% in 3 years.
These somewhat biased comments aside, this trial emphasizes
the need to clearly determine whether detection of asymptomatic
recurrent stenosis after CEA (or after carotid angioplasty with
stenting) and repeat intervention is of value in stroke prevention.
Perhaps only certain subsets of patients may benefit from ultra-
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